BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NanoSight Limited Release: ASTM Publishes E2834 Standard Defining Nanoparticle Tracking Analysis


7/3/2012 10:08:46 AM

Salisbury, UK, 3rd July 2012: NanoSight is delighted to welcome publication of American Society of Testing Materials ASTM E2834 - Standard Guide for Measurement of Particle Size Distribution of Nanomaterials in Suspension by Nanoparticle Tracking Analysis (NTA).

This document details application of Nanoparticle Tracking Analysis (NTA) to measurement of particle size distributions for suspended particles from ~10nm to the onset of sedimentation.

Duncan Griffiths, NanoSight's USA West Sales Manager comments "This document has taken almost three years to develop. It provides a rigorous review of the core science driving Brownian motion and the derived parameters of mean, mode, percentile values and concentration. The scrutiny of demanding third-party experts has been fundamental in producing a thorough appraisal of NTA. The result is a meticulous presentation of science and methodology. We are delighted".

The UK's National Physical Laboratory (NPL) has seen NanoSight develop NTA since its early days more than five years ago. Helen Sharman from NPL comments: "NPL has been working on the characterization of nanomaterials for many years, in-part collaborating with NanoSight. The nanomaterials team has followed the development of the NTA technique with great interest due to its unique capability in the area of nanometrology. As the UK's national measurement institute, NPL recognizes the importance of this standard and the capability of the NanoSight instrumentation to provide consistent, precise and comparable data."

NanoSight CEO Jeremy Warren adds "Whilst this standard is a milestone, it is also a building block. Many NanoSight users have requested this definition of the technique as they present data in research papers and to regulatory bodies for product approvals and clinical trials. We will now move to provide industry with test methods for specific materials to help lock down SOPs. The timing of this publication is helpful as the European Commission move to consider methodologies to address the characterization challenges of their recently-published definition of nanomaterials. Here we see a significant role for NTA's unique nanoparticle counting capability".

About NanoSight:

NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument.

NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements assess the surface charge on particles. NTA's particle-by-particle methodology goes beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.

NanoSight's simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.

NanoSight has installed more than 450 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 400+ third party papers citing NanoSight results, consolidating NanoSight's leadership position in nanoparticle characterization. For more information, visit www.nanosight.com

For further information:

Please contact NanoSight direct or their marketing agency, Talking Science:

NanoSight Limited

Minton Park

London Road

Amesbury SP4 7RT UK

T +44(0)1980 676060

F +44(0)1980 624703

www.nanosight.com

jeremy.warren@nanosight.com

Talking Science Limited

39 de Bohun Court

Saffron Walden

Essex CB10 2BA UK

T +44(0)1799 521881

M +44(0)7843 012997

www.talking-science.com

jezz@talking-science.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES